BDNF修饰骨髓间充质干细胞治疗AD的实验研究的开题报告VIP专享

精品文档---下载后可任意编辑BDNF 修饰骨髓间充质干细胞治疗 AD 的实验讨论的开题报告Title：BDNF-modified bone marrow mesenchymal stem cell therapy for Alzheimer’s disease: An experimental studyIntroduction：Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the progressive loss of cognitive function and memory. Currently, there is no cure for AD. However, stem cell therapy has emerged as a promising treatment option for this condition due to the potential of stem cells to repair damaged tissues. Bone marrow mesenchymal stem cells (BMSCs) are particularly promising, as they can differentiate into a variety of cell types and are easily accessible for transplantation. Furthermore, brain-derived neurotrophic factor (BDNF) has been shown to improve cognitive function in AD patients. Therefore, the aim of this study is to investigate the therapeutic potential of BDNF-modified BMSCs in the treatment of AD.Research Question：Can BDNF-modified BMSC therapy effectively improve cognitive function in AD rats?Hypothesis：BDNF-modified BMSC therapy will improve cognitive function in AD rats compared to non-modified BMSC therapy or no treatment.Methodology：The study will use a rat model of AD induced by the administration of amyloid-β peptide. BMSCs will be isolated from the bone marrow of the rats and cultured in vitro. The BMSCs will then be transfected with a BDNF-expressing lentivirus (experimental group) or a control lentivirus (control group). The rats will be divided into three groups: an experimental group receiving BDNF-modified BMSCs, a control group receiving non-modified BMSCs, and a sham group receiving no treatment. Cognitive function will be assessed using the Morris water maze test, and the effects on neuron 精品文档---下载后可任意编辑survival and synaptic plasticity will be assessed using immunohistochemistry, Western blotting, and electron microscopy.Anticipated results：It is anticipated that BDNF-modified BMSC therapy will result in significant improvements in cognitive function compared to non-modified BMSC therapy or no treatment. Additionally, there may be an increase in neuron survival and synaptic plasticity in the brains of rats receiving BDNF-modified BMSCs.